Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beta globin transduced bone marrow cells - San Rocco Therapeutics/Memorial Sloan-Kettering Cancer Center

Next Previous
Search
Drug Profile

Beta globin transduced bone marrow cells - San Rocco Therapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: 2009 EGT-produced vector; Autologous CD34+ cells transduced with TNS9.3.55; Autologous CD34+ stem cells - EGT; Lentiglobin; Thalagen; Thalassaemia gene therapy - EGT; TNS9-3-55 transduced CD34 cells

Latest Information Update: 25 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; San Rocco Therapeutics
  • Class Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements; Gene transference; Haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Beta-thalassaemia

Most Recent Events

  • 25 Mar 2025 Beta globin transduced bone marrow cells are still in phase I trial for Beta-thalassaemia in USA (IV, Infusion)
  • 25 Mar 2025 San Rocco Therapeutics plans a phase I/II trial of Beta globin transduced bone marrow cells for the treatment of Beta-thalassaemia in 2026 (San Rocco Therapeutics Pipeline, March 2025)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Beta-thalassaemia in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top